ライフサイエンスコーパス: cholesterol-lowering

1 nriched functional foods are widely used for cholesterol lowering.

2 ct on statin-induced low-density lipoprotein cholesterol lowering.

3 dditional evidence of statin benefits beyond cholesterol lowering.

4 from intensive low-density lipoprotein (LDL)-cholesterol lowering.

5 ipid levels alone, suggesting effects beyond cholesterol lowering.

6 suggesting that the effect is independent of cholesterol lowering.

7 oped to meet the challenge of more intensive cholesterol lowering.

8 and antiproliferative actions independent of cholesterol lowering.

9 ary VV neovascularization, in the absence of cholesterol lowering.

10 cular effects of the statins, independent of cholesterol lowering.

11 secretion and especially in animal models of cholesterol lowering.

12 unctions can improve within hours or days of cholesterol lowering.

13 ted with future coronary risk independent of cholesterol lowering.

14 member 8 (ABCG8) did not associate with LDL cholesterol lowering.

15 004) despite similar low-density lipoprotein cholesterol lowering.

16 sclerosis plaque regression after aggressive cholesterol lowering.

17 cardiovascular disease risk, despite plasma cholesterol lowering.

18 The cholesterol-lowering abilities of rice bran's fiber and

19 the major phytocompounds responsible for the cholesterol lowering ability of apples.

20 works and provides a potential mechanism for cholesterol-lowering action of FGF19.

21 The cholesterol-lowering action of simvastatin was monitored

22 Despite well-known cholesterol-lowering action of statins, their mechanisms

23 risk of AD, which has been attributed to the cholesterol-lowering actions of these drugs.

24 inflammatory actions are distinct from their cholesterol-lowering actions.

25 LOX-1 receptor is related to statin-mediated cholesterol-lowering activity is unknown.

26 l absorption and may account for part of the cholesterol-lowering activity of corn oil previously att

27 ition of FXR activation is the basis for the cholesterol-lowering activity of guggulsterone.

28 ion, the present study demonstrates a marked cholesterol-lowering activity of proteins from L. angust

29 analogs that bind to NPC1L1 exhibit in vivo cholesterol-lowering activity, whereas compounds that do

30 f a key intermediate in the synthesis of the cholesterol lowering agent, atorvastatin.

31 mg, a more intensive low-density lipoprotein cholesterol lowering agent, reduced both first and subse

32 Consistently, the cholesterol-lowering agent (pravastatin sodium) downregu

33 e, the predicted systems pharmacology of the cholesterol-lowering agent ezetimibe corroborates its po

34 ments included aspirin use, treatment with a cholesterol-lowering agent, cardiac catheterization, and

35 Furthermore, treating zebrafish with a cholesterol-lowering agent, ezetimibe, reduced susceptib

36 CONTEXT: Atorvastatin calcium (ATV), a cholesterol-lowering agent, suffers from poor systemic a

37 nd 6 months after treatment with probucol, a cholesterol-lowering agent.

38 s a probe to study HCV replication, and as a cholesterol-lowering agent.

39 clerosis; however, additional or alternative cholesterol lowering agents are needed for patients who

40 in treatments for hypercholesterolemia with cholesterol lowering agents, cardiovascular disease stil

41 implications for the development of improved cholesterol lowering agents.

42 ene cyclase inhibitors with high efficacy as cholesterol-lowering agents and of different chemical st

43 Within just a few years, four new LDL-cholesterol-lowering agents have received regulatory app

44 Maternal treatment with cholesterol-lowering agents or antioxidants greatly redu

45 Statins are widely used as cholesterol-lowering agents that also decrease inflammat

46 Statins are potent, cholesterol-lowering agents with newly appreciated, broa

47 Here, cholesterol-lowering agents, 3-hydroxy-3-methylglutaryl

48 ul (guggul) have been widely used in Asia as cholesterol-lowering agents, and their popularity is inc

49 Statins, extensively used as cholesterol-lowering agents, have recently been identifi

50 a potential target for novel antibiotics and cholesterol-lowering agents.

51 availability of effective and well-tolerated cholesterol-lowering agents.

52 For these SNPs, the cholesterol-lowering allele consistently was associated

53 Exposures: Low-density lipoprotein cholesterol-lowering alleles in or near NPC1L1, HMGCR, P

54 es, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited.

55 However, lovastatin (a cholesterol lowering and anti-inflammatory drug) adminis

56 The TR beta subtype is involved in cholesterol lowering and possibly elevating metabolic ra

57 studies have suggested associations between cholesterol lowering and psychological well-being.

58 esis and serves as an alternative target for cholesterol-lowering and antibiotic drugs.

59 yocardial Ischemia Reduction with Aggressive Cholesterol Lowering) and PROVE-IT (Pravastatin or Atorv

60 l homeostasis through liver X receptor (LXR; cholesterol-lowering)- and sterol regulatory element-bin

61 ti-cancer, anti-hypertension, anti-diabetic, cholesterol-lowering, and cognition-improving.

62 years due to their health benefits, such as cholesterol lowering, anti-inflammatory, anti-atherogeni

63 g lifestyle factors, blood pressure control, cholesterol-lowering, antithrombotic therapy, and fixed-

64 The major determinant of cholesterol lowering appears to be nut dose rather than

65 Benefits of plant sterols (PS) for cholesterol lowering are compromised by large variabilit

66 The benefits of plant sterols (PSs) for cholesterol lowering are hampered by large heterogeneity

67 rticipants responding to PS consumption with cholesterol lowering better than the mean cholesterol lo

68 The difference in total- and LDL-cholesterol lowering between the 2 soy-protein supplemen

69 The cholesterol-lowering blockbuster drug pravastatin can be

70 lar function in diabetic mice independent of cholesterol lowering but via effects dependent on choles

71 ta, these data are the first to suggest that cholesterol lowering by pravastatin might increase the r

72 Furthermore, cholesterol lowering by statins, methyl-beta-cyclodextri

73 otective effects that are independent of LDL-cholesterol lowering called pleiotropic effects.

74 n found that some probiotic bacteria possess cholesterol-lowering capabilities.

75 and-binding domain (LBD) in complex with the cholesterol-lowering compound SR12813 and a 25 amino aci

76 SK9 expression by berberine (BBR), a natural cholesterol-lowering compound.

77 potential benefit of low-density lipoprotein cholesterol lowering could not be excluded.

78 t that individual variation in response to a cholesterol-lowering diet is a familial trait.

79 A high-MUFA, cholesterol-lowering diet may be preferable to a low-fat

80 We studied the effect on LDL cholesterol of cholesterol-lowering diets with varying amounts of lean

81 For rosuvastatin, a cholesterol-lowering drug and OATP1A/1B substrate, the l

82 e KRAS(G12D)-induced LCH-like mouse with the cholesterol-lowering drug atorvastatin ameliorated the p

83 The medications were pravastatin, a cholesterol-lowering drug for the prevention of cardiova

84 metabolites in fungi, such as lovastatin, a cholesterol-lowering drug from Aspergillus terreus.

85 d not forget that niacin is an effective LDL-cholesterol-lowering drug in patients with high LDL leve

86 tal structures of hCE1 in complexes with the cholesterol-lowering drug mevastatin, the breast cancer

87 tivating the apoAI gene or administering the cholesterol-lowering drug probucol.

88 The cholesterol-lowering drug simvastatin has been shown to

89 The cholesterol-lowering drug simvastatin promotes bone form

90 n of hPXR both alone and in complex with the cholesterol-lowering drug SR12813 at resolutions of 2.5

91 treatment of macrophages with lovastatin, a cholesterol-lowering drug that blocks farnesylation and

92 when the mice were treated with Ezetimibe, a cholesterol-lowering drug that blocks intestinal dietary

93 s statins, account for the great majority of cholesterol-lowering drug use.

94 Simvastatin is a cholesterol-lowering drug whose pleiotropic effects may

95 iation between statin use (vs. no use of any cholesterol-lowering drug) and the risk of having abnorm

96 cholesterol diet, with or without ezetimibe (cholesterol-lowering drug), and high-fat/high-cholestero

97 lytic process involved in the synthesis of a cholesterol-lowering drug, atorvastatin (Lipitor), and w

98 tin, a Food and Drug Administration-approved cholesterol-lowering drug, could protect against nigrost

99 n of Atorvastatin (AT) versus the non-statin cholesterol-lowering drug, Ezetimibe (EZT) on severity o

100 holesterol homeostasis and its response to a cholesterol-lowering drug, ezetimibe.

101 Similarly, pravastatin, another cholesterol-lowering drug, suppressed microglial inflamm

102 a decade after the approval of the last LDL-cholesterol-lowering drug, the cholesterol absorption in

103 disease; and 44% and 50% taking statin-class cholesterol-lowering drugs and aspirin, respectively.

104 nd the development of the newly approved LDL-cholesterol-lowering drugs and critically review their e

105 coronary events in comparison to usual-care cholesterol-lowering drugs and whether perfusion changes

106 ssociated with increased AD risk, and use of cholesterol-lowering drugs associated with decreased ris

107 An important example of such drugs are the cholesterol-lowering drugs called 'statins', including Z

108 Current use of cholesterol-lowering drugs for five or more years was no

109 Statins were designed as cholesterol-lowering drugs for the prevention of coronar

110 antihyperglycaemic drugs and non-statin LDL-cholesterol-lowering drugs in patients with type 2 diabe

111 to oral hypoglycemic, antihypertensive, and cholesterol-lowering drugs into its Medicare Advantage q

112 later in life and maternal intervention with cholesterol-lowering drugs or antioxidants reduce postna

113 Here, I propose that rather than being cholesterol-lowering drugs per se, statins act as vitami

114 the common chiral side chain of statin-type cholesterol-lowering drugs such as Lipitor (atorvastatin

115 s that could cause adverse drug reactions to cholesterol-lowering drugs such as statins.

116 Statins are widely prescribed cholesterol-lowering drugs that are a first-line treatme

117 Statins are cholesterol-lowering drugs that have been proven in rand

118 e A (HMG-CoA) reductase enzyme (statins) are cholesterol-lowering drugs that have shown promise as th

119 Statins are cholesterol-lowering drugs that inhibit 3-hydroxy-3-meth

120 Statins are effective cholesterol-lowering drugs that reduce the risk of cardi

121 Statins are widely used cholesterol-lowering drugs that selectively inhibit the

122 ls using non-physiological high fat diets or cholesterol-lowering drugs to modify plasma cholesterol,

123 acy of statins, the most prescribed class of cholesterol-lowering drugs used for the prevention and t

124 between high circulating cholesterol levels, cholesterol-lowering drugs, and breast cancer are confli

125 etitively, reduce LDL levels more than other cholesterol-lowering drugs, and lower triglyceride level

126 of renal patients of interventions (such as cholesterol-lowering drugs, antihypertensives, aspirin,

127 t studies have indicated statins, a class of cholesterol-lowering drugs, as a potential therapy for A

128 lutaryl-CoA reductase inhibitors, a class of cholesterol-lowering drugs, could interrupt Ang II signa

129 itors, which are the most commonly used oral cholesterol-lowering drugs, have immunomodulatory proper

130 Statins, cholesterol-lowering drugs, inhibit these deleterious pr

131 e relative risk for current users of general cholesterol-lowering drugs, mostly statins in this cohor

132 ned the association between long-term use of cholesterol-lowering drugs, predominantly statins, and t

133 late caveolin/caveolae expression, including cholesterol-lowering drugs, reversed the increased CCE a

134 ns with the 231 patients who did not use any cholesterol-lowering drugs, statin use was associated wi

135 The widely used cholesterol-lowering drugs, statins, were reported to re

136 Statins are cholesterol-lowering drugs, targeting HMG-CoA reductase,

137 cal pathway has given rise to a new class of cholesterol-lowering drugs, the proprotein convertase su

138 In the analysis of general cholesterol-lowering drugs, we ascertained 3420 cases of

139 effects of rechallenge with statins or other cholesterol-lowering drugs.

140 and cardiac events compared with usual-care cholesterol-lowering drugs.

141 hway and is inhibited by statins, a class of cholesterol-lowering drugs.

142 Saponins have plasma cholesterol lowering effect in humans and are important

143 The cholesterol lowering effect of BAS may translate into a

144 n and oral bioavailability, and the greatest cholesterol-lowering effect in comparison with PB suspen

145 onal guidelines, increased the total and LDL cholesterol-lowering effect of a low-fat diet.

146 hesized that inflammation could diminish the cholesterol-lowering effect of a reduced-fat/low-cholest

147 This unexpected cholesterol-lowering effect of CXCR7 is beneficial for a

148 es probably underestimated the potential LDL cholesterol-lowering effect of diet.

149 Health claims regarding the cholesterol-lowering effect of soluble fiber from oat pr

150 ty in dialysis patients is likely due to the cholesterol-lowering effect of systemic inflammation and

151 with apple consumption, probably due to the cholesterol-lowering effect of the main bioactive compou

152 sterol and colorectal cancer risk suggests a cholesterol-lowering effect of undiagnosed malignancy.

153 Nuts have a cholesterol-lowering effect, but the relation between nu

154 r the use of statins, independently of their cholesterol-lowering effect, in early stages of diabetic

155 fibre could be designed that yields the best cholesterol-lowering effect, using experiences in tailor

156 ct on diabetic neuropathy independent of its cholesterol-lowering effect.

157 ), and most of them demonstrated significant cholesterol lowering effects in a cholesterol-fed rat (C

158 In addition to their cholesterol lowering effects, statins have pleiotropic a

159 syllium husk, have been shown to augment the cholesterol-lowering effects of a low-fat diet in person

160 We examined the cholesterol-lowering effects of a proprietary Chinese re

161 In addition to the profound cholesterol-lowering effects of apheresis, other potenti

162 Furthermore, AAT3 augments LDL cholesterol-lowering effects of ApoB-ASO.

163 PCSK9 could be a novel mechanism behind the cholesterol-lowering effects of PUFAs.

164 r these clinical benefits stem from powerful cholesterol-lowering effects of statins or whether they

165 gests that this mechanism is involved in the cholesterol-lowering effects of the extract.

166 determine the state of the evidence for the cholesterol-lowering effects of three selected fibres an

167 lupus-like autoimmunity independent of their cholesterol-lowering effects via a shift from a Th1 to a

168 Besides their cholesterol-lowering effects, statins also possess broad

169 In addition to their cholesterol-lowering effects, statins inhibit cell proli

170 nic inflammation, in addition to their serum cholesterol-lowering effects, we hypothesized that stati

171 rest for new therapeutics with anticancer or cholesterol-lowering effects.

172 inal drug molsidomine, which may explain its cholesterol-lowering effects.

173 statins may be in part independent of their cholesterol-lowering effects.

174 ins appeared to be independent of the drugs' cholesterol-lowering effects.

175 id constituents in nuts that have additional cholesterol-lowering effects.

176 In summary, this study demonstrates the cholesterol-lowering efficacy of short-term feeding of t

177 rials using statin drugs, which suggest that cholesterol lowering from high to moderate levels is saf

178 Results: Low-density lipoprotein cholesterol-lowering genetic variants at NPC1L1 were inv

179 statin with expected low-density lipoprotein cholesterol lowering >/= 50%) after adjustment for patie

180 The ability of cholesterol lowering HMG-CoA reductase inhibitors (stati

181 Orally administered cholesterol-lowering HMG-CoA reductase inhibitors (known

182 th cholesterol lowering better than the mean cholesterol lowering in all participants were 4.25 (95%

183 re well established as first-line agents for cholesterol lowering in cardiovascular disease, with acc

184 ld interrupt Ang II signaling independent of cholesterol lowering in endothelial cells.

185 They also suggest cholesterol lowering in extra-hepatic tissues by statins

186 Intensive low-density lipoprotein cholesterol lowering in patients improved the rate of pl

187 These data support further LDL-cholesterol lowering in patients with cardiovascular dis

188 vention statin trials led to more widespread cholesterol lowering in patients with coronary disease a

189 of benefit and safety of more intensive LDL cholesterol lowering in patients with diabetes and estab

190 ynthesis, serves as an a priori predictor of cholesterol lowering in response to PS consumption.

191 Low-density lipoprotein (LDL) cholesterol lowering in response to PSs was associated w

192 therapies for low-density lipoprotein (LDL)-cholesterol lowering in the management of atheroscleroti

193 No study, however, has assessed benefits of cholesterol lowering in the primary prevention of corona

194 This study confirms the need for early cholesterol lowering in this high-risk population.

195 vailable agents may allow more effective LDL-cholesterol lowering in those patients intolerant of cur

196 rolonged half-life and increased duration of cholesterol lowering in two species in vivo by binding t

197 so as brain-protective, hepatoprotective and cholesterol lowering ingredients.

198 an be slowed and, in some cases, reversed by cholesterol-lowering interventions.

199 Plasma cholesterol lowering is beneficial in patients with athe

200 safely reduced, whether the mechanism of LDL-cholesterol lowering matters, and whether ever more aggr

201 7A1-rs3808607) T/T homozygotes showed no LDL cholesterol lowering (mean +/- SEM: -0.05 +/- 0.07 mmol/

202 Purpose Cholesterol-lowering medication (CLM) has been reported

203 Associations include use of cholesterol-lowering medication and intraretinal hyperre

204 Conclusion Cholesterol-lowering medication during adjuvant endocrin

205 When 32 men taking cholesterol-lowering medication were excluded, the inter

206 nhibitors have become the preferred class of cholesterol-lowering medication with an increasing body

207 a dietary supplement or if she needs to take cholesterol-lowering medication, and if so, whether she

208 s revealed that simvastatin, an FDA-approved cholesterol-lowering medication, inhibited STAT1 activat

209 ia (5.44-6.99 mmol/L) who were not receiving cholesterol-lowering medication.

210 l cholesterol level <200 mg/dL and no use of cholesterol-lowering medication; blood pressure 120/</=8

211 he onion sign disproportionately were taking cholesterol-lowering medications (P=0.025).

212 cholesterol determination or reported using cholesterol-lowering medications and who participated in

213 The increased use of cholesterol-lowering medications has apparently accounte

214 However, the age-adjusted use of cholesterol-lowering medications increased from 1.6% to

215 s antiplatelet, blood pressure-lowering, and cholesterol-lowering medications into a single pill asso

216 sociation was found for the use of nonstatin cholesterol-lowering medications or cyclooxygenase 2 inh

217 of changes in dietary fat intake and use of cholesterol-lowering medications to changes in concentra

218 The increased use of cholesterol-lowering medications was estimated to accoun

219 5.2 mmol/L (200 mg/dL) or who reported using cholesterol-lowering medications, 69.5% reported having

220 blood pressure, use of antihypertensive and cholesterol-lowering medications, smoking, total cholest

221 erol <5.17 mmol/L (<200 mg/dL) and not using cholesterol-lowering medications, systolic blood pressur

222 l cholesterol > or =200 mg/dL or who were on cholesterol-lowering medications, the proportion of men

223 f 2 and 4 egg yolks/d by older adults taking cholesterol-lowering medications.

224 and quantified exposure to statins and other cholesterol-lowering medications.

225 e are confounded by postrandomization use of cholesterol-lowering medications.CVD risk in postmenopau

226 ocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) C-reactive protein sub-stu

227 yocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study was designed to brid

228 yocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study.

229 yocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study.

230 the Myocardial Ischemia Reduction With Acute Cholesterol Lowering (MIRACL) trial at baseline and afte

231 ntly transferred to monacolin J to yield the cholesterol-lowering natural product lovastatin.

232 However, the unexpected LDL-cholesterol lowering observed in the Milk group, and the

233 These findings suggest that the effects of cholesterol lowering on endothelial function are more co

234 hese agents may exert effects independent of cholesterol lowering on TGFbeta signaling in the heart.

235 h it is unclear whether this is secondary to cholesterol lowering or other mechanisms.

236 Despite aggressive low-density lipoprotein cholesterol lowering, patients continue to be at signifi

237 ought to investigate the associations of LDL cholesterol-lowering PCSK9 variants with type 2 diabetes

238 This suggests that cholesterol lowering per se has anti-inflammatory effect

239 , but whether this is due to pleiotropism or cholesterol lowering per se is unclear.

240 The cholesterol-lowering pharmaceutical gemfibrozil is a rel

241 It has also been suggested that the cholesterol-lowering potential of KJM may be greater tha

242 (1-->4)-beta-D-glucan), a dietary fibre with cholesterol lowering properties.

243 FR171456 is a natural product with cholesterol-lowering properties in animal models, but it

244 oducible assay useful for characterising the cholesterol-lowering properties of bioactive food compon

245 Cholesterol-lowering properties of phytosterols and phyt

246 These data suggest that non-cholesterol-lowering properties of statins may favorably

247 ists with beneficial low-density lipoprotein cholesterol-lowering properties that may provide additio

248 that soluble fibers, like pectin, had strong cholesterol-lowering properties that were beneficial in

249 ti-inflammatory effects independent of their cholesterol-lowering properties, which have been attribu

250 chemic cardiomyopathy independently of their cholesterol-lowering properties.

251 er of pathobiological processes beyond their cholesterol-lowering properties.

252 ll benefits of statin therapy may exceed its cholesterol-lowering properties.

253 st cancer cells, which is independent of its cholesterol-lowering property.

254 ne compound, compactin, the precursor of all cholesterol-lowering statins, was of particular interest

255 s study population, most of whom were taking cholesterol-lowering statins.

256 erest for the production of natural dyes and cholesterol-lowering statins.

257 es risk of aggressive prostate cancer, while cholesterol lowering strategies may confer protective be

258 0002), whereas HS individuals failed to show cholesterol lowering (TC: -0.09 +/- 0.09 mmol/L; P = 0.2

259 chanism, safety and efficacy of emerging LDL-cholesterol lowering therapies.

260 ption of proven effective therapies, such as cholesterol-lowering therapies and blood pressure manage

261 nal studies; however, randomized trials with cholesterol-lowering therapies in individuals with estab

262 Therefore, cholesterol-lowering therapies may induce dynamic and be

263 current efficacious low-density lipoprotein-cholesterol-lowering therapies.

264 standardize the background statin-based LDL cholesterol-lowering therapy and to establish participan

265 Residual confounding by cholesterol-lowering therapy and trans fat or limited va

266 lease niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduc

267 hypercholesterolaemia who were on stable LDL cholesterol-lowering therapy for at least 4 weeks; all p

268 Six months of cholesterol-lowering therapy has no significant effect o

269 The target population for consideration of cholesterol-lowering therapy in a large, integrated heal

270 the use of intensive low-density lipoprotein cholesterol-lowering therapy in high-risk older persons

271 Cholesterol-lowering therapy leads to plaque stabilizati

272 on is the most important mechanism, by which cholesterol-lowering therapy reduces both the incidence

273 f adults aged 40 to 65 years recommended for cholesterol-lowering therapy under each guideline were s

274 of dialysis patients are better targets for cholesterol-lowering therapy.

275 may contribute to the beneficial effects of cholesterol-lowering therapy.

276 recommended for outcome-related benefits of cholesterol-lowering therapy.

277 chemia suggests that low-density lipoprotein cholesterol-lowering thresholds for ischemia and major a

278 Intensive LDL-cholesterol lowering to a mean of 79 mg/dl with atorvast

279 ization by 30%, compared with less intensive cholesterol-lowering to a mean of 101 mg/dl with atorvas

280 in particular from early and more aggressive cholesterol-lowering treatment (eg, with PCSK9 inhibitor

281 monitoring patients who are receiving stable cholesterol-lowering treatment could be lengthened.

282 Effective cholesterol-lowering treatment started in early childhoo

283 guideline instead proposes implementation of cholesterol-lowering treatment using evidenced-based int

284 The use of cholesterol-lowering treatment, angiography, and revascu

285 After 6 months of cholesterol-lowering treatment, only MR imaging measurem

286 fective statin-based low-density lipoprotein cholesterol-lowering treatment.

287 CL (Myocardial Ischemia Reduction with Acute Cholesterol Lowering) trial, respectively.

288 yocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.

289 w-up of statin-based low-density lipoprotein cholesterol lowering trials improves the understanding o

290 Low-density lipoprotein cholesterol lowering was less in subjects with higher (>

291 LDL cholesterol lowering was significantly greater with high

292 rculating lipid levels or statin-induced LDL-cholesterol lowering were tested for association with re

293 emonstrates significant and dose-related LDL cholesterol lowering with a PCSK9 monoclonal antibody in

294 rpose of this study was to determine whether cholesterol lowering with atorvastatin improves walking

295 his report describes the effect of intensive cholesterol lowering with atorvastatin on the incidence

296 Intensive cholesterol lowering with atorvastatin over 16 weeks in

297 ify individuals who would derive maximum LDL cholesterol lowering with PS consumption.

298 ebo-controlled trials have demonstrated that cholesterol lowering with statin therapy reduces the inc

299 herapeutic dietary options for enhancing LDL-cholesterol lowering, with inclusion of plant stanols/st

300 ts of the history of low-density lipoprotein-cholesterol lowering, with the discovery of the low-dens